Nyrada Inc (nyr) Logo

Nyrada Inc (NYR)

___:___ · Healthcare

NYR Chart


NYR's Principal Activity is the development of therapeutic treatments for cardiovascular, neurological and inflammatory/autoimmune diseases, testing and optimization of novel drug candidates while building on the Company's patent portfolio.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -36.01%
vs ASX 200 (1yr) -39.73%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,575 of 2,413
Sector Rank 138 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies GTG / PAA / BDA
EPS -$0.023
DPS $0.00
Book Value Per Share $0.09

Broker Consensus

NYR is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Nyrada Inc (NYR) is a preclinical stage, drug development company. The Company is in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. The Company's two lead programs centre on cholesterol-lowering and brain injury. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury (TBI).

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Gordon NSW 2072
Website www.nyrada.com
Registry Automic Group
Auditor William Buck Audit (VIC) Pty Ltd
Date Listed 16 Jan 2020

Upcoming Calendar (Forecasted)

Date Event
29/08/2022 Report (Prelim)
29/08/2022 Report (Annual)
24/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Ian Edward Dixon Founder,Non-Executive Director Sep 2020

Dr Ian Edward Dixon

Founder,Non-Executive Director

Mr Dixon, In 2011, Co-Founded Cynata Inc, a company that is progressing the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX-CYP). Dr Dixon is a co-inventor of the LEAP Technology owned by Exopharm. Dr Dixon brings to the Board a technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development. Dr Dixon is also a founder of Exopharm Ltd. During the last three years, Dr Dixon has served as a director of the following listed companies: Medigard Ltd (ASX:MGZ) and Noxopharm Ltd (ASX:NOX

Mr Christopher Cox Non-Executive Director Nov 2019

Mr Christopher Cox

Non-Executive Director

Mr Cox is a Co-Founder and Managing Partner of Population Health Partners, L.P., a global private equity firm focused on innovative therapeutics with the potential to transform health outcomes for populations. Prior to that, from January 2012 to February 2020, he was a partner at Cadwalader, Wickersham & Taft LLP, where he also served as the Chairman of Cadwalader's Corporate Department and as a member of its Management Committee. He remains a Senior Attorney of Cadwalader. From February 2016 to March 2019, Chris was seconded to The Medicines Company, a global biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was responsible for business development and strategy. Prior to January 2012, he was a partner at Cahill Gordon & Reindel LLP. He also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a private investment holding company with interests in life sciences, entertainment and technology

Mr John Alexander Moore Non-Executive Chairman,Non-Executive Director Jun 2019

Mr John Alexander Moore

Non-Executive Chairman,Non-Executive Director

Mr Moore currently serves as Chairman of Trialogics, a clinical trial informatics business and Chairman of Scientific Industries (SCND-OTCQB) a producer of laboratory instruments for the life sciences industry. He was CEO of Acorn Energy from 2006 to 2015, during which time the CoaLogix business was acquired for US$11 million and sold for US$101 million, and the Comverge business listed in the US before its sale to Constellation Energy. In 2002 he was a Partner and CEO of Edson Moore Healthcare Ventures and acquired for US$148 million a portfolio of sixteen drug delivery investments from Elan Pharmaceuticals.

Mr Ruediger Weseloh Non-Executive Director Jun 2019

Mr Ruediger Weseloh

Non-Executive Director

Mr Weseloh is a Senior Director of Business Development at Merck KgaA, Darmstadt, Germany, where over a period of 15 years he has led more than 60 transactions for its pharmaceutical division, completing deals across the drug development value chain in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before Merck KgaA, Dr Weseloh spent 5 years as a Biotech/Pharma Equity Analyst at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen Dr Weseloh also serves on the Supervisory Board of Cytotools AG, Freiburg, German

Mr Marcus Frampton Non-Executive Director Jun 2019

Mr Marcus Frampton

Non-Executive Director

Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC), the US$82 billion sovereign wealth fund for the State of Alaska. Mr Frampton manages the investment team at APFC and leads all investment decisions related to APFC's investment portfolio within the guidelines established by APFC's Board of Trustees. Before joining the APFC in 2012, Mr Frampton held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005), to private equity investing at PCG Capital Partners (2005-2010), and acted as an executive of a private equity-backed portfolio company at LPL Financial (2010-2012). In addition to his duties at the APFC, Mr Frampton is also a shareholder and sits on the board of directors of Scientific Industries, Inc., a leading manufacturer of laboratory equipment and the owner of intellectual property related to bioprocessing systems

Mr Peter Ashley Marks Non-Executive Director Aug 2017

Mr Peter Ashley Marks

Non-Executive Director

Mr Marks has over 35 years' experience in corporate advisory and investment banking. Throughout his long career, he has specialised in capital raising, IPOs, cross border M&A transactions, corporate underwriting, and venture capital transactions for companies in Australia, the US and Israel. He has been involved in a broad range of transactions with a special focus on the life sciences, biotechnology, medical technology and high-tech segments. He has served as both an Executive and Non-Executive Director of several different entities which have been listed on the ASX, NASDAQ, and AIM markets. He is currently a Director of Alterity Therapeutics Limited (ASX:ATH and NASDAQ:ATHE), Non-Executive Director of Noxopharm Limited (ASX: NOX) and Non-Executive Director of Elsight Ltd (ASX:ELS). Until 31 March 2020, he was also a Non-Executive Director of Fluence Corporation Ltd (ASX: FLC).

Mr David James Franks Company Secretary N/A
Mr James Bonnar Chief Executive Officer N/A

Director Transactions

NYR directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
29/06/21 John Moore Issued 76,923 $0.26 $20,000 Placement
29/06/21 Peter Marks Issued 200,000 $0.26 $52,000 Placement
29/06/21 Marcus Frampton Issued 75,000 $0.26 $19,500 Placement
29/06/21 Ruediger Weseloh Issued 100,000 $0.26 $26,000 Placement
29/06/21 Ian Dixon Issued 192,308 $0.26 $50,000 Placement
29/06/21 Christopher Cox Issued 625,000 $0.26 $162,500 Placement
02/03/21 John Moore Buy +19,000 $0.35 $6,650 On-market trade
02/03/21 John Moore Buy +500 $0.204 $102 As advised by the company
23/02/21 Marcus Frampton Buy +25,000 $0.357 $8,925 On-market trade
18/01/21 Ian Dixon Issued 1,800,000 $0.40 $720,000 Director remuneration
25/11/20 John Moore Buy +32,000 $0.206 $6,600 On-market trade
24/11/20 Marcus Frampton Buy +35,000 $0.21 $7,350 On-market trade
10/09/20 John Moore Buy +32,500 $0.21 $6,825 On-market trade
23/04/20 John Moore Buy +35,000 $0.168 $5,882 On-market trade

Director Interests

The current holdings of NYR directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Marcus Frampton 30/06/2021 245,075 N/A 1,800,000 N/A
Christopher Cox 30/06/2021 N/A 1,425,000 1,800,000 N/A
Ruediger Weseloh 30/06/2021 100,000 N/A 1,800,000 N/A
John Moore 30/06/2021 358,423 N/A 3,600,000 N/A
Ian Dixon 30/06/2021 N/A 10,114,033 5,999,400 N/A
Peter Marks 30/06/2021 N/A 250,000 2,600,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 13, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Noxopharm Limited 33,373,245 21.39%
Altnia Holding Pty Ltd (I Dixon Family A/C) 9,921,725 6.36%
Sunset Capital Management Pty Ltd (Sunset Superfund A/C) 2,548,197 1.63%
Colin Housely & Freda Housely(Cm Housley & Fv Housley Fam) 1,863,725 1.19%
Kohen Enterprises Pty Ltd 1,735,000 1.11%
Canary Capital Pty Ltd 1,701,923 1.09%
Symphony Capital Holdings Llc 1,425,000 0.91%
Professor Gary David Housley 1,411,411 0.90%
Kyriaco Barber Pty Ltd 1,400,000 0.90%
John W King Nominees Pty Ltd 1,242,483 0.80%
Goodridge Foundation Pty Ltd (Goodridge Foundation A/C) 1,212,416 0.78%
Dixson Trust Pty Limited 1,100,000 0.71%
Mr Graham Arthur Robinson 1,082,888 0.69%
Himstedt & Co Pty Ltd (The Himstedt Family A/C) 1,057,000 0.68%
Rhlc Pty Limited (Rhlc S/F A/C) 1,000,000 0.64%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon (Mcmahon Super Fund A/C) 924,616 0.59%
Mr Jason Fernando Haddock 873,146 0.56%
Sandhurst Trustees Ltd (Wunala Capital A/C) 831,250 0.53%
Mr Anthony John Locantro 734,540 0.47%
Mr John Gardner 734,384 0.47%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 15 397 254 873 225 1,764

Substantial Shareholders

No Substantial Shareholders for NYR in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
29-06-21 Altnia Holdings Pty Ltd 192,308 7.16 6.48

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.31 30 June
2020 $0.175 30 June
NYR Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.